Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 7;13(2):187.
doi: 10.3390/cancers13020187.

Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

Salomon M Stemmer  1 , Nebojsa S Manojlovic  2 , Mihai Vasile Marinca  3 , Petar Petrov  4 , Nelly Cherciu  5 , Doina Ganea  6 , Tudor Eliade Ciuleanu  7 , Ioana Adriana Pusca  8 , Muhammad Shaalan Beg  9 , William T Purcell  10 , Adina-Emilia Croitoru  11 , Rumyana Nedyalkova Ilieva  12 , Sladjana Natošević  13 , Amedeia Lavinir Nita  14 , Dimitar Nikolaev Kalev  15 , Zivit Harpaz  16 , Motti Farbstein  16 , Michael H Silverman  16 , David Bristol  16 , Inbal Itzhak  16 , Pnina Fishman  16
Affiliations

Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

Salomon M Stemmer et al. Cancers (Basel). .

Abstract

Namodenoson, an A3 adenosine-receptor agonist, showed promising results in advanced hepatocellular carcinoma (HCC) and moderate hepatic dysfunction (Child-Pugh B; CPB) in a phase I/II clinical study. This phase II study investigated namodenoson as second-line therapy in such patients. Patients were randomized 2:1 to twice a day (BID) namodenoson (25 mg; n = 50) or placebo (n = 28). The primary endpoint (overall survival [OS]) was not met. Median OS was 4.1/4.3 months for namodenoson/placebo (hazard ratio [HR], 0.82; 95% confidence interval [CI] 0.49-1.38; p = 0.46). Pre-planned subgroup analysis of CPB7 patients (34 namodenoson-treated, 22 placebo-treated) showed a nonsignificant improvement in OS/progression-free survival (PFS). OS: 6.9 versus 4.3 months; HR, 0.81; 95% CI: 0.45-1.43, p = 0.46. PFS: 3.5 versus 1.9 months; HR, 0.89; 95% CI: 0.51-1.55, p = 0.67 (log-rank test). The difference in 12-month OS was significant (44% versus 18%, p = 0.028). Response rates were determined in patients for whom ≥ 1 assessment post-baseline was available (34 namodenoson-treated, 21 placebo-treated). Partial response was achieved by 3/34 (8.8%) and 0/21 (0%) patients, respectively. Namodenoson was well-tolerated, with a safety profile comparable to that of the placebo group. No treatment-related deaths were reported; no patients withdrew due to toxicity. In conclusion, namodenoson demonstrated a favorable safety profile and a preliminary efficacy signal in HCC CPB.

Keywords: Child–Pugh B; hepatocellular carcinoma; namodenoson; overall survival; randomized clinical trial.

PubMed Disclaimer

Conflict of interest statement

Salomon M. Stemmer and Michael H. Silverman are consultants and stakeholders at Can-Fite BioPharma; Zivit Harpaz, Motti Farbstein, Inbal Itzhak and Pnina Fishman are employed by and stakeholders at Can-Fite BioPharma; David Bristol is a consultant at Can-Fite BioPharma; The remaining authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart of patient recruitment, treatment, and follow-up. F/U, follow-up; ICF, informed consent form; ITT, intention to treat; Pt, patient.
Figure 2
Figure 2
Kaplan–Meier curves by treatment group (namodenoson 25 mg/kg twice a day (BID) and placebo) for all patients and Child–Pugh B7 (CPB7) patients. (a) overall survival (OS) in all patients; (b) progression-free survival (PFS) in all patients; (c) OS in CPB7 patients; (d) PFS in CPB7 patients.
Figure 3
Figure 3
Forest plot summarizing exploratory overall survival (OS) subgroup analysis comparing patients assigned to receive namodenoson 25 mg/kg twice a day (BID) versus placebo. AFP, Alpha-fetoprotein; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EHS, extrahepatic spread; H, hazard ratio; PVT, portal vein thrombosis.
See this image and copyright information in PMC

References

    1. Global Burden of Disease Cancer Collaboration. Fitzmaurice C., Akinyemiju T.F., Al Lami F.H., Alam T., Alizadeh-Navaei R., Allen C., Alsharif U., Alvis-Guzman N., Amini E., et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4:1553–1568. - PMC - PubMed
    1. Granito A., Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and child-pugh-turcotte class b cirrhosis. Lancet Oncol. 2017;18:e101–e112. doi: 10.1016/S1470-2045(16)30569-1. - DOI - PubMed
    1. FDA Website Sorafenib Package Insert. [(accessed on 4 January 2020)]; Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl....
    1. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., Sherman M., Schwartz M., Lotze M., Talwalkar J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl. Cancer Inst. 2008;100:698–711. doi: 10.1093/jnci/djn134. - DOI - PubMed
    1. NIH U.S. National Library of Medicine, Clinical Trials Data Base. [(accessed on 12 July 2020)]; Available online: ClinicalTrials.gov.

Grants and funding

LinkOut - more resources